A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers
To compare the difference of a marker of cellular proliferation in all bronchial biopsy specimens of former smokers stratified by lung cancer risk, collected before and after treatment per patient between the enzastaurin and placebo groups.
Checked against the public recordLast updated Sep 21, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Prevention
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Eli Lilly and Company
- Interventions being studied
- Drug: Enzastaurin; Drug: Placebo
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Sputum atypia participants with normal sputum cytology will be removed from the study) * Metaplasia or dysplasia on at least one bronchoscopy specimen * History of cigarette smoking ≥30 Pack Years * Quit smoking ≥1 year prior to study entry * Able to undergo bronchoscopy and helical computed tomography (CT) scanning of the chest * Able to swallow tablets Exclusion Criteria: * Blood clotting abnormalities * Current smoking within the past 1 year * Unwillingness to abstain from smoking while enrolled in the clinical trial or unwillingness to avoid significant second hand smoke exposure * Evidence for lung cancer or carcinoma in situ * Active cardiovascular disease * Current illicit drug or alcohol abuse
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.Tampa, Florida
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 21, 2020. Always confirm current availability with the study team.